Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 vs lapatinib + capecitabine in HER2-positive advanced breast cancer
CTR20201708Phase 3Completed
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Aug 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anvatabart opadotin in breast cancer, sponsored by Zhejiang Medicine Co., Ltd.. Started Aug 2020; status: completed.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20201708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201708.